Citations
Mayo Clinic
2 citation(s) found for "Young, Joseph".
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)
Bock, Allison M. , Mwangi, Raphael , Shreve, J. T., Khurana, Arushi , Wang, Y., Nowakowski, Grzegorz S. , Young, Joseph , Ataei, F., Thorpe, Matthew , Pritchett, Joshua C. , Maurer, Matthew J. , Paludo, Jonas , Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Young, J. R.
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 344-345
Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis
Chen, Yue , Cheng, Xingyu , Sun, Chenyu , Kim, Na Hyun , Kailas, Sujatha, Qureshi, Faisal, Karadsheh, Zeid, Wu, Yile , Hu, Lei , Zhou, Zhen , Bhan, Chandur , Kim, Keun Young , Manem, Raveena, Cheng, Ce , Zhou, Qin , Sun, Chenyu
Postgraduate Medical Journal | September 30, 2021 | Volume: 98 | Issue: 1165 | Pages: 866-870
10.1136/postgradmedj-2021-140432
| PMID 37063031
AbstractObjectivesStudies on the association between metformin use and the risk of oesophageal cancer (OC) have generated controversial findings. This updated meta-analysis was conducted to reassess the effects of metformin on OC.MethodsA comprehensive search strategy was conducted to select relevant studies from origination to February 2021. Heterogeneity was evaluated through the Q test and I2 statistics. HRs and 95% CIs were pooled through either random-effect or fixed-effect models. Meta-regression, subgroup analyses, sensitivity analysis and publication bias diagnosis were also performed.ResultsSeven studies with 5 426 343 subjects were included. Metformin use was associated with reduced risk of OC (HR=0.69, 95% CI 0.54 to 0.87, p<0.001). Sensitivity analysis suggested that the results were relatively stable.ConclusionMetformin is associated with a reduced risk of OC. More well-designed studies are still needed to further elaborate on these associations.PROSPERO registration numberCRD42021237127.